Heartseed and Novo Nordisk Enter into Global Collaboration and Licence Agreement for Stem Cell-Based Therapy for Heart Failure

Heartseed Inc. and Novo Nordisk A/S announced that they have entered into a collaboration and licence agreement for the development, manufacturing and commercialisation of Heartseed’s asset HS-001, an investigational cell therapy using purified cardiomyocytes derived from induced pluripotent stem cells, which is currently under development by Heartseed for the treatment of heart failure.